Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Lpath Inc. (LPTN) Adds Two Patents to Growing Portfolio of Antibody Therapeutics

|Includes: Apollo Endosurgery (APEN)

Lpath Inc., a leading lipidomics-based antibody therapeutics company, announced that the U.S. Patent and Trademark Office (USPTO) has issued the company two patents, bringing the company’s patent portfolio to 20 issued U.S. patents.

These newly issued patents cover the methods and composition of matter for Lpath’s anti-Sphingosine-1-Phosphate (S1P) antibody, sonepcizumab, which is the active component in Lpath’s two lead compounds, iSONEP™ and ASONEP™. The patents also have claims of the amino acid sequences of sonepcizumab and claims for the treatment of cancer, cardiovascular and cerebrovascular disease.

Lpath recently completed two early-stage clinical trials; in one study, iSONEP was evaluated in a phase I trial in wet-AMD subjects; the other evaluated ASONEP in a phase I trial in cancer subjects.

Lpath said its next plan of action is to continue moving forward with two iSONEP phase 2 trials. The first trial, which is currently underway, was designed to evaluate the safety and efficacy of iSONEP in patients with RPE Detachment (NYSEMKT:PED), for which there is no approved drug. The soon-to-begin Nexus Study will evaluate the safety and efficacy in wet-AMD patients without PED.

Lpath’s plans for next year include an ASONEP phase 2 trial in renal cell carcinoma patients.

The company’s comprehensive patent portfolio now includes 20 U.S. issued patents, five international patents, 132 patent applications, 87 of which are international.

For more information visit Lpath.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net